Start at the source.
Work with established Ghana-based relationships to build a traceable supply of Voacanga africana root bark.
Sourcing relationships
Pharmaceutical-grade alkaloids, from the source.
Built at the source, not bought on a market.
Ethovoa Sciences is a development-stage pharmaceutical company working toward GMP-qualified supply of voacangine, the registered starting material for ibogaine hydrochloride, from Voacanga africana sourced in Ghana.
B2B. We supply licensed manufacturers and research institutions only.
A focused programme. A clear chemical pathway.
Voacanga africana root bark
Voacangine
Iboga alkaloid APIs
Our approach
A clear path from source to science.
Ethovoa is developing an integrated model that connects botanical sourcing and upstream processing in Ghana with specialist pharmaceutical development partners. We are building toward a qualified, reproducible supply of voacangine and downstream APIs.
Develop the extract.
Develop a consistent voacangine intermediate, with characterisation and quality requirements agreed with our development partners.
Upstream development
Build toward GMP.
Engage a qualified Contract Development and Manufacturing Organization to establish GMP-grade voacangine, and the pathway onward to ibogaine hydrochloride.
Partner discussions
Origin / Ghana, West Africa
Local roots. Global perspective.
A long-term asset, not a commodity.
We treat the source material as a long-term asset, not a commodity. Our sourcing follows the Nagoya Protocol's access and benefit-sharing framework, with formal engagement through Ghana's national competent authority. The genetic resource itself, not merely the finished extract, is the basis of that commitment.
- Harvested on a rotational basis to ensure botanical viability
- Documented origin and formal chain of custody
- Nagoya Protocol access and benefit-sharing framework
- Upstream processing located in country, at origin
Our objective is a sourcing and processing framework that supports the rigorous regulatory requirements of future pharmaceutical customers.
Organization
Experience built over years.
Our team combines pharmaceutical chemistry, GMP manufacturing experience and direct in-country relationships across Ghana's growing regions. It was built over years, not assembled for this project.
Ian MacKenna
Founder, Chief Executive Officer and Lead Chemist
Ian holds a chemistry background from the University of New Orleans and has worked specifically in ibogaine chemistry for approximately three years. He has spent four months in country in Ghana building the sourcing and processing relationships that the programme is founded on.
He is directly responsible for the synthesis pathway, the technical documentation package and engagement with development and manufacturing partners. He speaks and moderates regularly at conferences in the field.
Behind the programme
Ian is supported by a board and operating group whose contributions span the disciplines this programme depends on. We introduce them directly in partner conversations.
- The originator of the Voacanga total alkaloid extraction methodology, as chairman
- Supply chain leadership with an established Ghanaian processor network
- In-country chemistry and facility management, resident in Ghana
- Corporate structure and business development, from prior company builds
- Ghana relations, with long-standing community and institutional ties
Our development focus
Voacangine first. A wider horizon.
Voacangine is the common intermediate for a family of iboga alkaloid APIs, ibogaine hydrochloride among them. A focused programme today, with room to serve that wider family, and the broader potential of Voacanga-derived alkaloids, over time.
01
GMP voacangine
02
Downstream iboga alkaloid APIs
03
Broader alkaloids
Lead development programme
Primary pipeline
Our near-term product is GMP-grade voacangine, derived from Ghana-sourced botanical material and supplied as a finished intermediate in its own right. We are seeking a qualified CDMO for starting-material assessment, analytical and process development, and tech transfer at scale. Downstream APIs, ibogaine hydrochloride included, are subsequent steps rather than the first one.
Current stage: development and partner evaluation. No commercial GMP supply is being offered at this stage.
Development goals are not statements of regulatory approval or GMP certification. Product specifications, manufacturing scope and availability will be established through the appropriate development and qualification work. Read the full development notice.
Let's start a conversation
The next step starts together.
Have the capabilities, perspective or research needs to help shape this programme? We supply licensed manufacturers and research institutions.
Direct
- General and partnership
- [email protected]
- Founder and lead chemist
- [email protected]
Please do not include confidential technical information or patient data in an initial inquiry.